Hitomi Sumiyoshi Okuma

Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study

Takafumi Koyama, Toshio Shimizu, Yuki Kojima et al. · Cancer Discovery · 2023 · 43 citations

Medicine, Oncology, Pharmacology +13

MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform Trial

Hitomi Sumiyoshi Okuma, Kan Yonemori, Shoko Narita et al. · Clinical Pharmacology & Therapeutics · 2020 · 36 citations · Full text

Medicine, Oncology, Translational Sciences +17

Impact of ALK Inhibitors in Patients With <i>ALK</i>-Rearranged Nonlung Solid Tumors

Yuki Takeyasu, Hitomi Sumiyoshi Okuma, Yuki Kojima et al. · JCO Precision Oncology · 2021 · 31 citations · Full text

Medicine, Oncology, Pharmacology +17

Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus.

Hitomi Sumiyoshi Okuma, Satoru Iwasa, Hirokazu Shoji et al. · PubMed · 2014 · 29 citations

Medicine, Oncology, Pharmacology +15

Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population

Shoko Noda‐Narita, Akihiko Shimomura, Asuka Kawachi et al. · Breast Cancer · 2019 · 26 citations · Full text

Medicine, Oncology, Pharmacology +16